EMA Authorised: Repatha (Evolocumab) — Amgen Europe B.V.

View source ↗

Summary

EU regulators authorised Repatha (evolocumab) for dyslipidemias and hypercholesterolemia; decision date 12/12/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypercholesterolemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Status: Authorised. Therapeutic area: Dyslipidemias;Hypercholesterolemia. MAH: Amgen Europe B.V.. Decision date: 12/12/2025